Online inquiry

IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13400MR)

This product GTTS-WQ13400MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13400MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9663MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ5891MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ9826MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ6835MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ15506MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ12538MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ14575MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ2483MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW